Comparative analysis of immunophenotypic abnormalities in cellular immunity of uremic patients undergoing either hemodialysis or continuous ambulatory peritoneal dialysis

被引:31
作者
Griveas, I
Visvardis, G
Fleva, A
Papadopoulou, D
Mitsopoulos, E
Kyriklidou, P
Manou, E
Ginikopoulou, E
Meimaridou, D
Paulitou, A
Sakellariou, G
机构
[1] Papageorgiou Gen Hosp, Dept Nephrol, Thessaloniki 56403, Greece
[2] Papageorgiou Gen Hosp, Dept Immunol, Thessaloniki 56403, Greece
关键词
cellular immunity; lymphocyte subsets counts; flow cytometry; hemodialysis; continuous ambulatory peritoneal dialysis;
D O I
10.1081/JDI-200056620
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aim. To investigate the abnormalities of cellular immune responses in patients on hemodialysis (HD) and in those on continuous ambulatory peritoneal dialysis (CAPD). Patients and Methods. Forty-five (45) healthy volunteers, 34 patients on HD therapy, and 37 patients on CAPD were recruited for the present study. Lymphocyte subpopulations (CD2+, CD3+, CD3+/ CD4+, CD3+/CD8+, CD3-/16+56+, CD19, and CD4/CD8) were determined by flow cytometry. Results. Lymphopenia, decreased absolute counts, and altered percentage values of CD3+, CD3+/ 4+, and CD19+ subpopulations were found in both patient groups. The HD and CAPD patients showed increased percentages of natural killer cells (CD3-/16+56+) compared to controls but CD4+/CD8+ ratio showed no significant changes among uremic patients and controls. Conclusions. Replacement therapy may contribute to the quantitative alterations of immune subsets found in HD and CAPD patients compared to normal subjects. We speculate that these changes account, at least in part, for the immune dysregulation observed in patients with chronic renal failure. Analysis of lymphocyte subsets will help the research and the evaluation of the possible causes of immunodeficiency in uremic patients undergoing replacement therapy and will probably contribute to more efficient and preventive strategies.
引用
收藏
页码:279 / 282
页数:4
相关论文
共 25 条
[1]  
ALEXIEWICZ JM, 1990, J AM SOC NEPHROL, V1, P236
[2]  
Carvounis CP, 2000, PERITON DIALYSIS INT, V20, P33
[3]  
CASCIANI CM, 1978, KIDNEY INT, V13, P49
[4]  
Chatenoud L, 1990, Adv Nephrol Necker Hosp, V19, P259
[5]  
COEN G, 1997, KIDNEY INT, V52, P79
[6]   ACTIVATION OF IMMUNOCOMPETENT CELLS IN THE PERITONEUM OF PATIENTS TREATED WITH CAPD [J].
DAVIES, SJ ;
SUASSUNA, J ;
OGG, CS ;
CAMERON, JS .
KIDNEY INTERNATIONAL, 1989, 36 (04) :661-668
[7]  
DescampsLatscha B, 1996, SEMIN NEPHROL, V16, P183
[8]  
GERMENIS A, 2000, IMMUNOLOGY, P13
[9]  
GERMENIS A, 2000, IMMUNOLOGY, P407
[10]  
GIACCHINO F, 1984, PERITON DIALYSIS B, V4, P209